Fig. 3

Effect of ocrelizumab in CD19⁻CD3⁺ and CD19⁻CD3⁻ cells. A UMAP plot displays pre-gated CD3⁺ cells from the blood of CG, SID and EID patients. Colours correspond to PARC-guided clustering. Percentage of annotated T cell populations out of the total CD45⁺ cells from CG, SID and EID patients. B UMAP shows pre-gated CD19⁻CD3⁻ cells from the blood of CG, SID and EID patients. Colours correspond to PARC-guided clustering. Percentage of annotated CD19⁻CD3⁻ cell clusters out of the total CD45⁺ cells from CG, SID and EID patients. C Spearman correlation immune network with nodes visualizing immune subsets and lines displaying correlation coefficients between immune cell clusters. The size of the node represents the abundance of the immune cell subset and the colour nodes represent the immune type. Lines represent significant positive (red) and negative (blue) correlations between clusters. A, B Each data point corresponds to each individual, columns and error bars show mean ± SEM. P-values indicate the statistical differences after a GLM model with age, sex and type of MS as covariates. *adjusted p-value < 0.05, #unadjusted p-value < 0.05. Th T helper cells, Tregs regulatory T cells, Temra T effector memory re-expressing CD45RA cells, NKT natural killer T cells, DN double negative, DP double positive cells, NK natural killer cells, MDSCs myeloid-derived suppressor cells, pDCs plasmacytoid dendritic cells, mDCs myeloid dendritic cells, GLM multivariate general linear model, CG control group, SID standard interval dosing, EID extended interval dosing